

In the claims:

Please cancel claims 122, 124, 126, 127, 140, 184, 186, 188, 189 and 205 without prejudice, and add new claims 235-239.

---

1-112. (Canceled)

113. (Previously amended) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising:

contacting a multi-epitopic antigen present in a host's serum with a composition comprising a binding agent that specifically binds to a first epitope on the antigen, the binding agent present in the composition being non-radiolabeled, and allowing the binding agent to form a binding agent/antigen pair, whereby an effective host immune response is elicited against a second epitope on the antigen in the binding agent/antigen pair.

114. (Canceled)

115. (Previously amended) The method of Claim 113, wherein the host immune response comprises a cellular and humoral immune response.

116. (Previously amended) The method of claim 113, wherein the host immune response comprises a cellular immune response.

117. (Previously amended) The method of Claim 113, wherein the host immune response comprises a humoral immune response.

118. (Previously amended) The method of Claim 113, wherein the multi-epitopic *in vivo* antigen is a soluble antigen.

119. (Previously added) The method of Claim 118, wherein the soluble antigen is a soluble tumor-associated antigen.

120. (Previously added) The method of Claim 118, wherein the soluble antigen is associated with a human disease or condition.

121. (Previously added) The method of Claim 120, wherein the human disease or condition is cancer.

122. (Canceled)

123. (Currently amended) The method ~~if of~~ Claim ~~122-113~~, wherein the binding agent is an antibody is a murine monoclonal antibody or a polypeptide including an antigen binding portion thereof.

124. (Canceled)

Gz 125. (Currently amended) The method of Claim ~~113~~ 123, wherein the antibody binding agent is B43.13.

126. (Canceled)

127. (Canceled)

128. (Currently amended) The method of Claim ~~123-122~~, wherein the antibody comprises a native antibody.

129. (Previously amended) The method of Claim 113, wherein the antigen is CA125.

130. (Previously added) The method of Claim 129, wherein the level of CA125 in the host's serum is greater than 100U/ml.

131. (Currently amended) The method of Claim ~~122~~123, wherein the antigen is a soluble circulating antigen and the antigen is contacted with a sufficient amount of antibody to present all the circulating antigen to the immune system.

132. (Previously amended) The method of Claim 113, wherein the antigen is contacted with binding agent in an amount of from 0.1  $\mu$ g to 2 mg per kg of body weight of the host.

133. (Previously added) The method of Claim 132, wherein the antigen is contacted with binding agent in an amount from 1  $\mu$ g to 200  $\mu$ g per kg of body weight of the host.

134. (Previously added) The method of Claim 133, wherein allowing the binding agent to form a binding agent/antigen pair presents other epitopes on the antigen to the host's immune system.

Gr 135. (Previously added) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, comprising administering to the host a composition comprising a non-radiolabeled binding agent that specifically binds to an epitope on the antigen, thereby forming a binding agent/antigen pair, whereby an effective immune response is elicited against the antigen, the binding agent being present in the composition in an amount of from 0.1  $\mu$ g to 2 mg per kg of body weight of the host.

136. (Canceled)

137. (Previously amended) The method of Claim 135, wherein the antigen is a soluble antigen.

138. (Previously amended) The method of Claim 135, wherein the antigen is a tumor antigen.

139. (Previously added) The method of Claim 137, wherein the antigen is a tumor antigen.

140. (Canceled)

141. (Currently amended) The method of Claim 113, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, ~~one or more imaging reagents,~~ one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

142. (Previously amended) The method of Claim 113, wherein contacting comprises administering by any immunologically suitable route.

143. (Previously added) The method of Claim 142, wherein administering by any immunologically suitable routes comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

144. (Previously added) The method of Claim 142, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

145-169. Canceled.

72 170. (Currently amended) The method of Claim 135, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, ~~one or more imaging reagents~~, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

171. (Previously added) The method of Claim 135, wherein the composition is administered by any immunologically suitable route.

172. (Previously added) The method of Claim 171, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

173. (Previously added) The method of Claim 171, wherein-administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

174. (Previously amended) A method for inducing a therapeutic host immune response against a multi-epitopic in vivo antigen that does not elicit an effective host immune response, the method comprising contacting a multi-epitopic in vivo antigen present in a host's serum with a composition comprising a binding agent that specifically binds to an epitope on the antigen, the binding agent present in the composition being non-radiolabeled, and allowing the

binding agent to form a binding agent/antigen complex, wherein the binding agent/antigen complex elicits an effective host immune response against the multi-epitopic in vivo antigen.

175. (Previously added) The method of Claim 174, wherein the effective host immune response is elicited against an epitope on the binding agent/antigen complex.

176. (Canceled)

177. (Previously added) The method of Claim 174, wherein the effective host immune response comprises a cellular and humoral immune response.

Gr 178. (Previously added) The method of Claim 174, wherein the effective host immune response comprises a cellular immune response.

179. (Previously added) The method of Claim 174, wherein the effective host immune response comprises a humoral immune response.

180. (Previously added) The method of Claim 174, wherein the multi-epitopic in vivo antigen is a soluble antigen.

181. (Previously added) The method of Claim 180, wherein the soluble antigen is a soluble tumor-associated antigen.

182. (Previously added) The method of Claim 180, wherein the soluble antigen is associated with a human disease or condition.

183. (Previously added) The method of Claim 182, wherein the human disease or condition is cancer.

184. (Canceled)

185. (Currently amended) The method of Claim ~~174-184~~, wherein the binding agent is an antibody is a murine monoclonal antibody or a polypeptide including an antigen binding portion thereof.

186. (Canceled)

187. (Previously added) The method of Claim 174, wherein the binding agent is B43.13.

188. (Canceled)

189. (Canceled)

Gr 190. (Currently amended) The method of Claim ~~184-185~~, wherein the antibody comprises a native antibody.

191. (Previously added) The method of Claim 174, wherein the antigen is CA125.

192. (Previously added) The method of Claim 191, wherein the level of CA125 in the host's serum is greater than 100 U/ml.

193. (Currently amended) The method of Claim ~~184-185~~, wherein the antigen is soluble circulating antigen and the antigen is contacted with a sufficient amount of antibody to present all the circulating antigen to the immune system.

194. (Previously added) The method of Claim 174, wherein the antigen is contacted with binding agent in an amount from 0.1 µg to 2 mg per kg of body weight of the host.

195. (Previously added) The method of Claim 194, wherein the antigen is contacted with binding agent in an amount from 1 µg to 200 µg per kg of body weight of the host.

196. (Previously added) The method of Claim 174, wherein allowing the binding agent to form a binding agent /antigen complex presents other epitopes on the antigen to the host's immune system.

197. (Currently amended) The method of Claim 174, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, ~~one or more imaging reagents~~, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

198. (Previously added) The method of Claim 174, wherein contacting comprises administering by any immunologically suitable route.

G12 199. (Previously added) The method of Claim 198, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

200. (Previously added) The method of Claim 198, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

201. (Previously added) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, comprising administering to the host a composition comprising a non-radiolabeled binding agent that specifically binds to an epitope on the antigen, thereby forming a binding agent/antigen complex, whereby an effective immune response is elicited against the binding agent/antigen complex, the binding agent being present in the composition in an amount of from 0.1  $\mu$ g to 2 mg per kg of body weight of the host.

202. (Previously added) The method of Claim 201, wherein the antigen is a soluble antigen.

203. (Previously added) The method of Claim 201, wherein the antigen is a tumor antigen.

204. (Previously added) The method of Claim 202, wherein the antigen is a tumor antigen.

205. (Canceled)

206. (Currently amended) The method of Claim 201, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, ~~one or more imaging reagents~~, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

207. (Previously added) The method of Claim 201, wherein the composition is administered by any immunologically suitable route.

208. (Previously added) The method of Claim 207, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

G2  
209. (Previously added) The method of Claim 207, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

210-234. (Withdrawn)

235. (New) The method according to any one of claims 115-121, 129, 130, 132-135, 137-139, 141-144, 170-175, 177-183, 191-192, 194-204, or 206-209 wherein the binding agent is an antibody.

236. (New) The method of claim 235, wherein the antibody is a murine monoclonal antibody.

237. (New) The method of claim 235, wherein the antibody is an Ab1 antibody.

238. (New) The method according to any one of claims 123, 185, 190, or 193, wherein the antibody is an Ab1 antibody.

239. (New) The method according to claim 123 or 185 wherein the antibody or polypeptide including an antigen binding portion thereof is selected from the group consisting of a chimeric



*Gr* monoclonal antibody, a genetically engineered monoclonal antibody, a Fab fragment, a F(ab')<sub>2</sub> fragment, and a single chain fragment.

---